Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advanced non-small cell lung cancer.

M J Edelman1, S L Khanwani

  • 1University of Maryland Greenebaum Cancer Center, 22 S. Greene Street, Baltimore, MD 21201-1595, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

Treatment for advanced non-small cell lung cancer involves chemotherapy for good performance status patients. Second-line options and palliative care for poor performance status are discussed, alongside potential curative therapies for metastatic disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.

Clinical and translational science·2016
Same author

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

Sequential chemotherapy: rationale and clinical trial design in advanced non-small-cell carcinoma.

Clinical lung cancer·2004
Same author

Neoadjuvant chemotherapy in early-stage non-small cell lung cancer.

Expert review of anticancer therapy·2002

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Oncology

Background:

  • Advanced non-small cell lung cancer (NSCLC) necessitates histologic confirmation, staging, and performance status assessment.
  • Management strategies vary based on disease stage (IIIB/IV) and patient performance status (PS).

Purpose of the Study:

  • To outline current treatment guidelines for advanced non-small cell lung cancer.
  • To discuss first-line, second-line, and palliative care approaches.
  • To explore curative intent options for select metastatic NSCLC cases.

Main Methods:

  • Review of established phase II/III studies for chemotherapy regimens.
  • Evaluation of evidence for second-line therapies.
  • Consideration of palliative care and curative-intent treatments for specific metastatic scenarios.

Main Results:

  • Combination platinum-based chemotherapy (cisplatin/carboplatin) with agents like paclitaxel, gemcitabine, vinorelbine, docetaxel, or CPT-11 is recommended for PS 0-1 patients.
  • Docetaxel is supported as a second-line option; gemcitabine and paclitaxel may also show activity.
  • Single-agent chemotherapy (vinorelbine, gemcitabine) for PS 2, supportive care for poor PS, and surgery/radiotherapy for solitary metastases are discussed.

Conclusions:

  • Treatment selection for advanced NSCLC should balance efficacy, toxicity, and patient factors.
  • Careful patient selection and staging are crucial for optimizing outcomes.
  • Emerging targeted therapies offer future treatment avenues for NSCLC.

Related Experiment Videos